Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (151-160 of 294) with videos related to

Pageof 30
Sort By:
Bladder Cancer (Amsterdam, Netherlands)|November 4, 2024
Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder CancerParminder Singh, Leslie Ballas, Guru P Sonpavde, et al.
European Urology Focus|December 7, 2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 MutationsHeather H Cheng, Sam Callis, Evan Y Yu, et al.
International Journal of Cancer|July 17, 2003
Centrosomal abnormality is common in and a potential biomarker for bladder cancerFeng Jiang, Nancy P Caraway, Anita L Sabichi, et al.
BJU International|September 6, 2007
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcomeMatthew E Nielsen, Ganesh S Palapattu, Pierre I Karakiewicz, et al.
European Urology|April 3, 2017
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas DatasetWoonyoung Choi, Andrea Ochoa, David J McConkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohortSalahaldin A Tahir, Anna Frolov, Teresa G Hayes, et al.
Nature|December 4, 2014
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistanceAntonina V Kurtova, Jing Xiao, Qianxing Mo, et al.
Urology|September 19, 2006
Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomyShahrokh F Shariat, Ganesh S Palapattu, Gilad E Amiel, et al.
Urology|March 1, 2008
Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomyAmit Gupta, Yair Lotan, Patrick J Bastian, et al.
European Urology|October 3, 2006
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomyShahrokh F Shariat, Ganesh S Palapattu, Pierre I Karakiewicz, et al.
Pageof 30

Showing results (151-160 of 294) with videos related to

Sort By:
Pageof 30
Bladder Cancer (Amsterdam, Netherlands)|November 4, 2024
Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder CancerParminder Singh, Leslie Ballas, Guru P Sonpavde, et al.
European Urology Focus|December 7, 2025
Clinical Trial in Progress: SWOG S2210, a Phase 2 Study of Neoadjuvant Carboplatin for Localized High-risk Prostate Cancer with Germline BRCA1/2 MutationsHeather H Cheng, Sam Callis, Evan Y Yu, et al.
International Journal of Cancer|July 17, 2003
Centrosomal abnormality is common in and a potential biomarker for bladder cancerFeng Jiang, Nancy P Caraway, Anita L Sabichi, et al.
BJU International|September 6, 2007
A delay in radical cystectomy of >3 months is not associated with a worse clinical outcomeMatthew E Nielsen, Ganesh S Palapattu, Pierre I Karakiewicz, et al.
European Urology|April 3, 2017
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas DatasetWoonyoung Choi, Andrea Ochoa, David J McConkey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohortSalahaldin A Tahir, Anna Frolov, Teresa G Hayes, et al.
Nature|December 4, 2014
Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistanceAntonina V Kurtova, Jing Xiao, Qianxing Mo, et al.
Urology|September 19, 2006
Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomyShahrokh F Shariat, Ganesh S Palapattu, Gilad E Amiel, et al.
Urology|March 1, 2008
Outcomes of patients with clinical T1 grade 3 urothelial cell bladder carcinoma treated with radical cystectomyAmit Gupta, Yair Lotan, Patrick J Bastian, et al.
European Urology|October 3, 2006
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomyShahrokh F Shariat, Ganesh S Palapattu, Pierre I Karakiewicz, et al.
Pageof 30